SynAct Pharma: Funding, Investors & Team (Sep 2026)
SynAct Pharma AB is developing medications for severe worsening in inflammatory diseases. Their drug candidate AP1189 is designed to treat arthritis, including psoriatic arthritis, a type of acute joint disorder that affects around 30% of psoriasis patients. Preclinical studies indicate that AP1189 can decrease inflammation and speed up healing, potentially reducing joint damage caused by acute joint inflammation. The drug may be administered in tablet form once daily. Results from a phase I clinical study are expected to be released in Q2 2018. The company plans to begin preparations for a patient study while completing the phase I study. If AP1189 proves safe and well-tolerated in multiple doses, the goal is to submit a clinical trial application for patients with active arthritis. Following successful results in patients, SynAct Pharma AB plans to establish commercial partnerships with major pharmaceutical companies.
SynAct Pharma has raised $7.7M across 2 funding rounds on record, the most recent an undisclosed round of $1.8M announced in Jul 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
SynAct Pharma Company Profile and Key Stats
Latest funding round on record: Jul 2025.
SynAct Pharma Funding Rounds
SynAct Pharma raised $5.9M in an undisclosed round announced in Nov 2024.
8 months later, an undisclosed round of $1.8M was announced in Jul 2025.
SynAct Pharma Founders and Leadership Team
Contact details for the SynAct Pharma team: 1 of 1 has an email address on file.
Start 14-day free trial →SynAct Pharma Funding Compared to Other Biotechnology Startups
SynAct Pharma's latest round of $1.8M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like SynAct Pharma in Biotechnology and Lund
Companies Similar to SynAct Pharma
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
SynAct Pharma Funding FAQs
What does SynAct Pharma do?
SynAct Pharma AB is developing medications for severe worsening in inflammatory diseases. Their drug candidate AP1189 is designed to treat arthritis, including psoriatic arthritis, a type of acute joint disorder that affects around 30% of psoriasis patients. Preclinical studies indicate that AP1189 can decrease inflammation and speed up healing, potentially reducing joint damage caused by acute joint inflammation. The drug may be administered in tablet form once daily. Results from a phase I clinical study are expected to be released in Q2 2018. The company plans to begin preparations for a patient study while completing the phase I study. If AP1189 proves safe and well-tolerated in multiple doses, the goal is to submit a clinical trial application for patients with active arthritis. Following successful results in patients, SynAct Pharma AB plans to establish commercial partnerships with major pharmaceutical companies.
How much funding has SynAct Pharma raised?
SynAct Pharma has raised $7.7M across 2 rounds on record. The most recent is an undisclosed round of $1.8M announced in Jul 2025.
When did SynAct Pharma last raise funding?
SynAct Pharma's most recent funding round on record is an undisclosed round of $1.8M, announced in Jul 2025.
Who founded SynAct Pharma?
FundedIQ lists Jeppe Ovli Ovlesen (Founder) at SynAct Pharma.
Where is SynAct Pharma headquartered?
SynAct Pharma is based in Lund, Skane Lan, Sweden.
How many employees does SynAct Pharma have?
SynAct Pharma is in the 11-50 employee band.
How does SynAct Pharma's funding compare to other Biotechnology startups?
SynAct Pharma's latest round of $1.8M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's SynAct Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for SynAct Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.